Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).

被引：0
|
作者：
Cheng, Ann-Lii
Cornelio, Gerardo H.
Shen, Lin
Price, Timothy Jay
Yang, Tsai-Sheng
Chung, Ilk Joo
Dai, Guanghai
Lin, Jen-Kou
Sharma, Atul
Yeh, Kun-Huei
Ma, Brigette
Zaatar, Adel
Guan, Zhongzhen
Masood, Nehal
Srimuninnimit, Vichien
Yau, Thomas Cheung
Beler, Frank
Chatterjee, Suipto
Lim, Robert S. C.
机构：
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
[2] San Juan De Dios Hosp, Pasay City, Philippines
[3] Beijing Canc Hosp, Beijing, Peoples R China
[4] Univ Adelaide, Queen Elizabeth Hosp, Woodville, SA 5011, Australia
[5] Chang Gung Mem Hosp, Taoyuan, Taiwan
[6] Chonnam Natl Univ, Hwasun Hosp, Hwasuneup, South Korea
[7] Peoples Liberat Army, Gen Hosp, Beijing, Peoples R China
[8] Taipei Vet Gen Hosp, Taipei, Taiwan
[9] All India Inst Med Sci, New Delhi, India
[10] Hong Kong Canc Inst, Dept Clin Oncol, Sir Y K Pao Ctr Canc, State Key Lab Oncol South China, Sha Tin, Hong Kong, Peoples R China
[11] Chinese Univ Hong Kong, Prince Wales Hosp, Sha Tin, Hong Kong, Peoples R China
[12] Mt Miriam Canc Hosp, George Town, Malaysia
[13] Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China
[14] Aga Khan Univ & Hosp, Karachi, Pakistan
[15] Siriraj Hosp, Bangkok, Thailand
[16] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
[17] Merck KGaA, Darmstadt, Germany
[18] Natl Univ Hlth Syst, Singapore, Singapore
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 03期
关键词：
D O I：
10.1200/jco.2015.33.3_suppl.566
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
566
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
    Cheng, Ann-Lii
    Cornelio, Gerardo
    Shen, Lin
    Price, Timothy
    Yang, Tsai-Sheng
    Chung, Ik Joo
    Dai, Guang-Hai
    Lin, Jen-Kou
    Sharma, Atul
    Yeh, Kun-Huei
    Ma, Brigette
    Zaatar, Adel
    Guan, Zhongzhen
    Masood, Nehal
    Srimuninnimit, Vichien
    Yau, Thomas
    Gibbs, Peter
    Wang, Xiuwen
    Doval, Dinesh Chandra
    Oh, Seung-Taek
    Shim, Byoung Yong
    Gorospe, Charity
    Wang, Hwei-Ming
    Sirachainan, Ekaphop
    Hill, Andrew
    Suh, Kwang Wook
    Beier, Frank
    Chatterjee, Sudipto
    Lim, Robert
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : E73 - E88
  • [2] COST-EFFECTIVENESS ANALYSIS OF PANITUMUMAB plus FOLFOX COMPARED TO CETUXIMAB plus FOLFIRI AS FIRST-LINE TREATMENT FOR PATIENTS WITH WILD-TYPE (WT) RAS (EXONS 2, 3, AND 4 OF KRAS AND NRAS) METASTATIC COLORECTAL CANCER (MCRC) IN COLOMBIA
    Vargas-Valencia, J.
    Garcia Perlaza, J.
    VALUE IN HEALTH, 2015, 18 (07) : A460 - A460
  • [3] FOLFOX4 plus cetuximab administered weekly or every two weeks in first-line treatment of patients with KRAS and NRAS wild-type (wt) metastatic colorectal cancer (mCRC)
    Brodowicz, Thomas
    Vrbanec, Damir
    Kaczirek, Klaus
    Ciuleanu, Tudor-Eliade
    Knittelfelder, Regina
    Lindner, Elisabeth
    Messinger, Diethelm
    Zielinski, Christoph
    Streubel, Berthold
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [4] Final overall survival (OS) analysis of first-line (1L) FOLFOX-4 ± cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial.
    Qin, Shukui
    Guo, Weijian
    Xu, Jian-Ming
    Li, Qi
    Cheng, Ying
    Liu, Tian Shu
    Chen, Jiongjie
    Chen, Wen-Feng
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).
    Cheng, Ann-Lii
    Cornelio, Gerardo H.
    Shen, Lin
    Price, Timothy Jay
    Yang, Tsai-Shen
    Chung, Ik-Joo
    Dai, Guanghai
    Lin, Jen-Kou
    Sharma, Atul
    Yeh, Kun-Huei
    Ma, Brigette
    Zaatar, Adel
    Guan, Zhongzhen
    Masood, Nehal
    Srimuninnimit, Vichien
    Yau, Thomas Cheung
    Sarholz, Barbara
    Lim, Robert S. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Association between depth of response (DpR) and survival outcomes in RAS-wild-type (wt) patients with metastatic colorectal cancer (mCRC) receiving first-line FOLFOX or FOLFIRI plus cetuximab once-every-2-weeks in the APEC study
    Cheng, A. -L.
    Cornelio, G.
    Shen, L.
    Price, T.
    Yang, T. -S.
    Chung, I. -J.
    Dai, G. -H.
    Lin, J. -K.
    Sharma, A.
    Yeh, K. -H.
    Ma, B.
    Zaatar, A.
    Guan, Z. -Z.
    Masood, N.
    Srimuninnimit, V.
    Yau, T.
    Beier, F.
    Chatterjee, S.
    Lim, R.
    ANNALS OF ONCOLOGY, 2016, 27 : 123 - 124
  • [7] Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients
    Stintzing, S.
    Jung, A.
    Rossius, L.
    Modest, D. P.
    von Weikersthal, L. Fischer
    Decker, T.
    Moehler, M.
    Scheithauer, W.
    Kirchner, T.
    Heinemann, V.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S8 - S9
  • [8] Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab plus first-line FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.
    Price, Timothy Jay
    Shen, Lin
    Ma, Brigette
    Esser, Regina
    Chen, Wen-Feng
    Gibbs, Peter
    Lim, Robert S. C.
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study
    Pinto, C.
    Orlandi, A.
    Normanno, N.
    Maiello, E.
    Calegari, M. A.
    Antonuzzo, L.
    Bordonaro, R.
    Zampino, M. G.
    Pini, S.
    Bergamo, F.
    Tonini, G.
    Avallone, A.
    Latiano, T. P.
    Rosati, G.
    Pazzola, A.
    Ballestrero, A.
    Zaniboni, A.
    Roselli, M.
    Tamberi, S.
    Barone, C. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1390 - S1390
  • [10] Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC).
    Ciuleanu, T.
    Nikolic, V.
    Shmueli, E.
    Vrbanec, D.
    Plate, S.
    Krmpotic, Z. M.
    Dank, M.
    Purkalne, G.
    Brodowicz, T.
    Zielinski, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
12345